Implications of Changing the Diagnostic Criteria for Gestational Diabetes Mellitus (CDC4G): A Healthcare Cost Analysis Alongside a Stepped Wedge Cluster Randomised Trial
Authors:
Open Access
- 10 September 2025
- journal article
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
Abstract
Objective: To estimate the effect on healthcare resource use after introducing the World Health Organization diagnostic criteria (WHO‐2013) for gestational diabetes mellitus (GDM) compared to former criteria in Sweden (SWE‐GDM).Design: A cost‐analysis alongside the Changing Diagnostic Criteria for Gestational Diabetes (CDC4G) randomised controlled trial.Setting: Sweden, with risk‐factor based screening for GDM.Population: 47 080 pregnant women and their infants.Methods: A register‐based cost‐analysis from a healthcare perspective alongside a stepped‐wedge cluster RCT of switching from SWE‐GDM to WHO‐2013 criteria in 2018. Analyses were made on the population level and repeated in the subgroup affected by the intervention, that is, those with plasma glucose values between SWE‐GDM and WHO‐2013 criteria. Sensitivity analysis by bootstrapping was performed.Main Outcome Measures: Estimated costs for obstetric surveillance (including GDM‐management), delivery and neonatal healthcare until 28 days postpartum.Results: On a population level, the WHO‐2013 criteria were associated with increased costs of obstetric surveillance (adjusted mean [bootstrap confidence interval]) €94.0 [24.5–169.1], delivery care €20.4 [−33.5 to 75.4] and neonatal care €331.0 [75.1–589.0] per pregnancy, and in the affected subgroup €606.9 [377.7–872.4], €348.5 [126.0–542.0] and €129.3 [−559.0 to 980.9] respectively.Conclusions: Implementation of the WHO‐2013 criteria in Sweden was associated with increased costs for obstetric surveillance and delivery on a population level, driven by the affected subgroup. The increased costs for neonatal care were associated with large uncertainty. A detailed understanding of the changes in resource use can guide decisions to mitigate cost increases.Keywords
Funding Information
- Vetenskapsrådet (2018‐00470)
- Skånes universitetssjukhus (REGSKANE‐622891)
This publication has 27 references indexed in Scilit:
- Cost-effectiveness of diagnosis and treatment of early gestational diabetes mellitus: economic evaluation of the TOBOGM study, an international multicenter randomized controlled trialeClinicalMedicine, 2024
- Are costs derived from diagnosis-related groups suitable for use in economic evaluations? A comparison across nine European countries in the European Healthcare and Social Cost DatabaseThe European Journal of Health Economics, 2022
- Increasing prevalence of gestational diabetes mellitus when implementing the IADPSG criteria: A systematic review and meta-analysisDiabetes Research and Clinical Practice, 2021
- Health Economic Evaluation Alongside Stepped Wedge Trials: A Methodological Systematic ReviewPharmacoEconomics, 2020
- Gestational diabetes mellitusNature Reviews Disease Primers, 2019
- Gestational diabetes screening with the new IADPSG guidelines: a cost-effectiveness analysisAmerican Journal of Obstetrics and Gynecology, 2012
- A Multicenter, Randomized Trial of Treatment for Mild Gestational DiabetesNew England Journal of Medicine, 2009
- Characteristics of women giving birth at home in Sweden: A national register studyAmerican Journal of Obstetrics and Gynecology, 2006
- Modeling risk using generalized linear modelsJournal of Health Economics, 1999
- Pulling cost-effectiveness analysis up by its bootstraps: A non-parametric approach to confidence interval estimationHealth Economics, 1997